Essmol 3 PLUS Overdose

How do you administer this medicine?
sponsored

Consists of aceclofenac, paracetamol, serratiopeptidase

Overdose of Aceclofenac (Essmol 3 PLUS) in details

When a dose is taken in higher dose than the recommended doses, it is called Overdose. Overdose always needs a clinical supervision. Any medicine or drug when consumed in Overdose produces untoward side effects on one or various organs in the body. A medicine is excreted in the kidney or metabolized in the liver most of the times. This process goes without any hurdles when taken in normal dose, but when taken in an overdose, the body is not able to metabolize it or send it out properly which causes the effects of anoverdose.
sponsored

Symptoms: SR tab: Headache, nausea, vomiting, epigastric pain, GI irritation and bleeding, rarely diarrhoea, disorientation, excitation, coma, drowsiness, dizziness, tinnitus, hypotension, respiratory depression, fainting, occasionally convulsions. In cases of significant poisoning acute renal failure and liver damage are possible.

Gel: The low systemic absorption of topical aceclofenac renders overdosage extremely unlikely. In the event of accidental ingestion, resulting in significant systemic adverse effects, general therapeutic measures normally adopted to treat poisoning with NSAID should be used.

Treatment: Patients should be treated symptomatically as required. Within 1-hr of ingestion of a potentially toxic amount, activated charcoal should be considered. Alternatively, in adults, gastric lavage should be considered within 1-hr of ingestion of a potentially life-threatening overdosage. Good urine output should be ensured. Renal and liver function should be closely monitored. Patients should be observed for at least 4 hrs after ingestion of potentially toxic amounts. In case of frequent or prolonged convulsions, patients should be treated with diazepam IV. Other measures may be indicated by the patient's clinical condition. Specific therapies eg, dialysis or haemoperfusion are probable of no help in eliminating NSAIDs due to their high rate of protein-binding and extensive metabolism. Management of acute poisoning with NSAIDs essentially consists of supportive and symptomatic measures.

Aceclofenac (Essmol 3 PLUS) warnings

Warnings are a mix of Precautions. Contraindications and interactions and serious harmful effects associated with the medicine intake. A diabetic or Hypertensive patient need to be warned about few drug interactions. A known hypersensitivity patient needs to be careful about the reactions or anaphylactic shock. A pregnant woman or a breastfeeding woman should be warned of certain medications. A Hepatitis [liver disease] patient or a cardiac patient should avoid few drugs.
sponsored

Respiratory disorders:

Caution is required if administered to patients suffering from, or with a previous history of, bronchial asthma since NSAIDs have been reported to precipitate bronchospasm in such patients.

Cardiovascular, Renal and Hepatic Impairment:

The administration of an NSAID may cause a dose dependent reduction in prostaglandin formation and precipitate renal failure. Patients at greatest risk of this reaction are those with impaired renal function, cardiac impairment, liver dysfunction, those taking diuretics and the elderly. Renal function should be monitored in these patients.

Renal:

The importance of prostaglandins in maintaining renal blood flow should be taken into account in patients with impaired cardiac or renal function, those being treated with diuretics or recovering from major surgery. Effects on renal function are usually reversible on withdrawal of this medicine.

Hepatic:

If abnormal liver function tests persist or worsen, clinical signs or symptoms consistent with liver disease develop or if other manifestations occur (eosinophilia, rash), this medicine should be discontinued. Close medical surveillance is necessary in patients suffering from mild to moderate impairment of hepatic function. Hepatitis may occur without prodromal symptoms.

Use of this medicine in patients with hepatic porphyria may trigger an attack.

Cardiovascular and cerebrovascular effects:

Appropriate monitoring and advice are required for patients with a history of hypertension and/or mild to moderate congestive heart failure as fluid retention and oedema have been reported in association with NSAID therapy.

Gastrointestinal bleeding, ulceration and perforation:

GI bleeding, ulceration or perforation, which can be fatal, has been reported with all NSAIDs at any time during treatment, with or without warning symptoms or a previous history of serious GI events.

SLE and mixed connective tissue disease:

In patients with systemic lupus erythematosus (SLE) and mixed connective tissue disorders there may be an increased risk of aseptic meningitis.

Dermatological:

Serious skin reactions, some of them fatal, including exfoliative dermatitis, Stevens-Johnson syndrome, and toxic epidermal necrolysis, have been reported very rarely in association with the use of NSAIDs. Patients appear to be at highest risk for these reactions early in the course of therapy: the onset of the reaction occurring in the majority of cases within the first month of treatment. This medicine should be discontinued at the first appearance of skin rash, mucosal lesions, or any other sign of hypersensitivity.

Impaired female fertility:

The use of this medicine may impair female fertility and is not recommended in women attempting to conceive. In women who have difficulties conceiving or who are undergoing investigation of infertility, withdrawal of this medicine should be considered.

Hypersensitivity reactions:

As with other NSAIDs, allergic reactions, including anaphylactic/anaphylactoid reactions, can also occur without earlier exposure to the drug.

Haematological:

This medicine may reversibly inhibit platelet aggregation

Long-term treatment:

All patients who are receiving NSAIDs should be monitored as a precautionary measure e.g. renal failure, hepatic function (elevation of liver enzymes may occur) and blood counts.

Aceclofenac (Essmol 3 PLUS) precautions

Certain people who are very sick or very old or who are sensitive show an exacerbation of side effect of the drug which can turn dangerous at times. So, it is very important to remember the precautions while taking the medicine. Pregnancy and Breastfeeding are also special categories wherein extra care or precaution is needed when taking a drug. Few patients may have a hypersensitivity reaction to few medications, and that can be life-threatening rarely. Penicillin hypersensitivity is one example. Diarrhea, rashes are few other symptoms which need a watch. A patient with other co-existing diseases like liver disease, heart disease, kidney disease should take special precautions.
sponsored

Adverse reactions may be minimized by using the lowest effective dose for the shortest duration necessary to control symptoms.

The use of Aceclofenac (Essmol 3 PLUS) with concomitant NSAIDs including cyclooxygenase-2 selective inhibitors should be avoided.

Respiratory Disorders: Caution is required if administered to patients suffering from or with a previous history of bronchial asthma since NSAIDs have been reported to precipitate bronchospasm in such patients.

Cardiovascular, Renal and Hepatic Impairment: The administration of an NSAID may cause a dose dependent reduction in prostaglandin formation and precipitate renal failure. Patients at greatest risk of this reaction are those with impaired renal function, cardiac impairment, liver dysfunction, those taking diuretics and the elderly. Renal function should be monitored in these patients.

Renal: The importance of prostaglandins in maintaining renal blood flow should be taken into account in patients with impaired cardiac or renal function, those being treated with diuretics or recovering from major surgery. Effects on renal function are usually reversible on withdrawal of aceclofenac tablets.

Hepatic: If abnormal liver function tests persist or worsen, clinical signs or symptoms consistent with liver disease develop or if other manifestations occur, Aceclofenac (Essmol 3 PLUS) tablets should be discontinued. Close medical surveillance is necessary in patients suffering from mild to moderate impairment of hepatic function. Hepatitis may occur without prodromal symptoms.

Use of tablets in patients with hepatic porphyria may trigger an attack.

Cardiovascular and Cerebrovascular Effects: Appropriate monitoring and advice are required for patients with a history of HTN and/or mild to moderate CHF as fluid retention and edema have been reported in association with NSAID therapy.

Patients with uncontrolled HTN, CHF, established ischemic heart disease, peripheral arterial disease and/or cerebrovascular disease should only be treated with aceclofenac after careful consideration. Similar consideration should be made before initiating a long-term treatment of patients with risk factors for cardiovascular disease (eg, HTN, hyperlipidemia, diabetes mellitus, smoking).

Gastrointestinal Bleeding, Ulceration and Perforation: Gastrointestinal bleeding, ulceration or perforation, which can be fatal, has been reported with all NSAIDs at any time during treatment, with or without warning symptoms or a previous history of serious gastrointestinal events.

Close medical surveillance is imperative in patients with symptoms indicative of gastrointestinal disorders, with a history suggestive of gastrointestinal ulceration, with ulcerative colitis or with Crohn's disease, bleeding diathesis or hematological abnormalities.

The risk of gastrointestinal bleeding, ulceration or perforation is higher with increasing NSAID doses, in patients with a history of ulcer, particularly if complicated with hemorrhage or perforation, and in the elderly. These patients should commence treatment on the lowest dose available. Combination therapy with protective agents (eg, misoprostol or proton-pump inhibitors) should be considered for these patients and also for patients requiring concomitant low dose aspirin or other drugs likely to increase gastrointestinal risk.

Caution should be advised in patients receiving concomitant medications which could increase the risk of ulceration or bleeding eg, oral corticosteroids, anticoagulants eg, warfarin, selective serotonin-reuptake inhibitors or antiplatelet agents eg, aspirin.

When gastrointestinal bleeding or ulceration occurs in patients receiving aceclofenac, the treatment should be withdrawn.

NSAIDs should be given with care to patients with a history of gastrointestinal disease as these conditions may be exacerbated.

Systemic Lupus Erythematosus (SLE) and Mixed Connective Tissue Disease: In patients with SLE and mixed connective tissue disorders there may be an increased risk of aseptic meningitis.

Dermatological: Serious skin reactions, some of them fatal, including exfoliative dermatitis, Stevens-Johnson syndrome and toxic epidermal necrolysis, have been reported very rarely in association with the use of NSAIDs. Aceclofenac should be discontinued at the first appearance of skin rash, mucosal lesions or any other sign of hypersensitivity.

Hypersensitivity Reactions: As with other NSAIDs, allergic reactions including anaphylactic/anaphylactoid reactions, can also occur without earlier exposure to the drug.

Effects on Ability to Drive or Operate Machinery: Adverse effects eg, dizziness, drowsiness, fatigue and visual disturbances are possible after taking NSAIDs. If affected, patients should not drive or operate machinery.

Impairment of Fertility: The use of aceclofenac may impair female fertility and is not recommended in women attempting to conceive. In women who have difficulties conceiving or who are undergoing investigation of infertility, withdrawal of aceclofenac should be considered.

Use in

Elderly: The elderly have an increased frequency of adverse reactions to NSAIDs especially gastrointestinal bleeding and perforation which may be fatal.

Use in Lactation: In limited studies so far available, NSAIDs can appear in breast milk in very low concentrations. NSAIDs should, if possible, be avoided when breastfeeding.

The use of aceclofenac should therefore be avoided in pregnancy and lactation unless the potential benefits to the other outweigh the possible risks to the fetus.

What happens if I overdose Paracetamol (Essmol 3 PLUS)?

Seek emergency medical attention if you think you have used too much of this medicine.

The first signs of an Paracetamol (Essmol 3 PLUS) overdose include loss of appetite, nausea, vomiting, stomach pain, sweating, and confusion or weakness. Later symptoms may include pain in your upper stomach, dark urine, and yellowing of your skin or the whites of your eyes.

Overdose of Paracetamol (Essmol 3 PLUS) in details

When a dose is taken in higher dose than the recommended doses, it is called Overdose. Overdose always needs a clinical supervision. Any medicine or drug when consumed in Overdose produces untoward side effects on one or various organs in the body. A medicine is excreted in the kidney or metabolized in the liver most of the times. This process goes without any hurdles when taken in normal dose, but when taken in an overdose, the body is not able to metabolize it or send it out properly which causes the effects of anoverdose.
sponsored

Paracetamol (Essmol 3 PLUS) in massive overdosage may cause hepatic toxicity in some patients. In adults and children >12 years, hepatic toxicity may occur following ingestion of >7.5-10 g over a period of ≤8 hrs. Fatalities are infrequent (<3-4% of untreated cases) and have rarely been reported with overdoses of <15 g. In children <12 years, acute overdosage with Paracetamol (Essmol 3 PLUS) <150 mg/kg body weight have not been associated with hepatic toxicity. Early symptoms following a potentially hepatotoxic overdose may include: Nausea, vomiting, diaphoresis and general malaise. Clinical and laboratory evidence of hepatic toxicity may not be apparent until 48-72 hrs after ingestion. In adults and children >12 years, any individual presenting with an unknown amount of Paracetamol (Essmol 3 PLUS) ingested or with a questionable or unreliable history about the time of ingestion should have a plasma Paracetamol (Essmol 3 PLUS) level drawn and be treated with N-acetylcysteine. Do not await results of assays for plasma Paracetamol (Essmol 3 PLUS) levels before initiating treatment with N-acetylcysteine. The following additional procedures are recommended. Promptly initiate decontamination of the stomach. A plasma Paracetamol (Essmol 3 PLUS) assay should be obtained as early as possible, but not sooner than 4 hrs following ingestion. Liver function studies should be obtained initially and repeated at 24-hr intervals.

Serious toxicity or fatalities have been extremely infrequent following acute overdosage in young children, possibly because of differences in the way they metabolize Paracetamol (Essmol 3 PLUS). In children, the maximum potential amount ingested can be more easily estimated. If >150 mg/kg or an unknown amount of Paracetamol (Essmol 3 PLUS) was ingested, obtain a plasma Paracetamol (Essmol 3 PLUS) level as soon as possible but no sooner than 4 hrs following ingestion. If an assay cannot be obtained and the estimated Paracetamol (Essmol 3 PLUS) ingestion exceeds 150 mg/kg, dosing with N-acetylcysteine should be initiated and continued for a full course of therapy.

What should I avoid while taking Paracetamol (Essmol 3 PLUS)?

Do not use any other over-the-counter cough, cold, allergy, or pain medication without first asking your doctor or pharmacist. Paracetamol (Essmol 3 PLUS) is contained in many combination medicines. If you use certain products together you may accidentally use too much Paracetamol (Essmol 3 PLUS). Read the label of any other medicine you are using to see if it contains Paracetamol (Essmol 3 PLUS), acetaminophen or APAP. Avoid drinking alcohol while taking this medication. Alcohol may increase your risk of liver damage while taking Paracetamol (Essmol 3 PLUS).

Paracetamol (Essmol 3 PLUS) warnings

Warnings are a mix of Precautions. Contraindications and interactions and serious harmful effects associated with the medicine intake. A diabetic or Hypertensive patient need to be warned about few drug interactions. A known hypersensitivity patient needs to be careful about the reactions or anaphylactic shock. A pregnant woman or a breastfeeding woman should be warned of certain medications. A Hepatitis [liver disease] patient or a cardiac patient should avoid few drugs.

New Prescribed Uses of Paracetamol (Essmol 3 PLUS): Questions and Answers

October 20, 1998 - U.S. Food and Drug Administration

Q. What professional uses of aspirin are now indicated?

1) STROKES: Paracetamol (Essmol 3 PLUS) use is now recommended in both men and women to treat mini-strokes (transient ischemic attack --TIA) or ischemic stroke to prevent subsequent cardiovascular events or death.

2) HEART ATTACKS:

Paracetamol (Essmol 3 PLUS):

3) OTHER CORONARY CONDITIONS: Paracetamol (Essmol 3 PLUS) can be used to treat patients who have had certain revascularization procedures such as angioplasty, and coronary bypass operations -- if they have a vascular condition for which aspirin is already indicated.

4) RHEUMATOLOGIC DISEASES -- Paracetamol (Essmol 3 PLUS) is indicated for relief of the signs and symptoms of rheumatoid arthritis, juvenile rheumatoid arthritis, osteoarthritis, spondylarthropathies, and arthritis and pleurisy associated with systemic lupus erythematosus.

Q. What does this mean for doctors and medical practice?

A. Doctors and health care professionals will be provided with full prescribing information about the use of aspirin in both men and women who have had a heart attack, stroke, certain other cardiovascular conditions and rheumatologic diseases. For stroke and cardiovascular conditions, lower doses are recommended than those previously prescribed by physicians in practice. Information on the use of aspirin for rheumatologic diseases has also been expanded to include specific dosing information as well as information about side effects and toxicity. Thus, doctors will have full prescribing information on aspirin and the assurance that aspirin is a safe and effective treatment for heart attacks, strokes, certain other vascular conditions and rheumatologic diseases.

Q. What is the basis for the new prescribing information?

A. The new information on the uses of aspirin is based on scientific studies that support treatment with aspirin for heart attacks, strokes, and some related conditions. Convincing data support these uses in lower doses than previously believed to be effective in treating heart attacks and strokes in both men and women.

Q. What does this mean for patients?

A. Physicians will be better able to prescribe the proper doses for these uses for male and female patients with these medical conditions. Dose-related adverse events for patients with stroke and cardiovascular conditions should be minimized because lower dosages are recommended. The full prescribing information now provided for physicians who treat rheumatologic diseases will enhance the safe and effective prescribing of aspirin to these patients as well.

Q. Is FDA concerned that some patients may self-treat?

A. FDA emphasizes that consumers should not self-medicate for these serious conditions because it is very important to make sure that aspirin is their best treatment. In these conditions, the risk and benefit of each available treatment for each patient must be carefully weighed. Patients with these conditions should be under the care and supervision of a doctor.

Q. If a consumer is interested in using aspirin to prevent or treat symptoms of heart problems, what should he or she do?

A. Consumers should always first ask their doctor. In fact, aspirin products are labeled this way: "Important: See your doctor before taking this product for other new uses of aspirin because serious side effects could occur with self treatment."

Q. Do the data on treatment or prevention of cardiovascular effects pertain only to aspirin?

A. Yes. Although acetaminophen, ibuprofen, naproxyn sodium and ketoprofen are good drugs for pain and fever, as is aspirin, only aspirin has demonstrated a beneficial effect for heart attack and stroke.

Q. What should consumers be made aware of?

A. Consumers should be informed that these new professional uses of aspirin may be lifesaving when used upon the recommendation and under the supervision of a doctor. However, they must also be informed that even familiar and readily available products like aspirin may have important risks when used in new ways. For example, because aspirin can cause bleeding; in rare cases bleeding in the brain may occur in people who are using aspirin to prevent stroke. Therefore these new uses should be recommended and monitored by a physician.

Q. What should consumers who are taking low dose aspirin for disease maintenance or prevention know about alcohol use?

A. Patients who consume 3 or more alcoholic drinks every day should be counseled about the bleeding risks involved with chronic, heavy alcohol use while taking aspirin.

Q. Can consumers safely use aspirin to treat suspected acute heart attacks?

A. If consumers suspect they are having a heart attack, their most important action must be to seek emergency medical care immediately. The advise and supervision of a doctor should direct this use of aspirin and patients are encouraged to speak with their doctor about this use.

Q. What do we know about how aspirin works for heart conditions and stroke?

A. The mechanism by which aspirin works in the treatment of heart attack and stroke is not completely understood. However, as an antiplatelet drug, we do know that aspirin help reduce platelet clumping which helps cause blockage in blood vessels.

Q. Who should NOT take aspirin?

A. Generally, people who have:

Always check first with your doctor to determine whether the benefit of these professional uses of aspirin is greater than the risks to you.

Q. What other side effects are associated with aspirin?

A. There is a wide range of adverse reactions that may result from aspirin use including effects on the body as a whole, or on specific body systems and functions.

High doses can cause hearing loss or tinnitus-- ringing in the ears. (Note that this usually only occurs with large doses as prescribed in rheumatologic diseases and is rare in treatment with low doses used for cardiovascular purposes.)

Q. What is key message for Consumers?

A. The results of studies of people with a history of coronary artery disease and those in the immediate phases of a heart attack have proven to be of tremendous importance in the prevention and treatment of cardiovascular and cerebrovascular diseases.

Studies showed that aspirin substantially reduces the risk of death and/ or non-fatal heart attacks in patients with a previous MI or unstable angina pectoris which often occur before a heart attack. Patients with these conditions should be under the care and supervision of a doctor.

Paracetamol (Essmol 3 PLUS) has potential risks as well as benefits, like any drug. Patients should be careful to ask their doctor or health care professional before deciding whether aspirin is right for them and how much aspirin they should take.

Q. What were the major studies used to verify the effectiveness of aspirin for these indications?

A. Numerous studies both in the United States and abroad were evaluated to establish the safety and efficacy of aspirin for the cardiovascular and cerebrovascular indications and dosing information.

Major studies included:

ISIS - 2 (Second International Study of Infarct Survival) (Ref 7)

SALT (Swedish Paracetamol (Essmol 3 PLUS) Low-Dose Trial (Ref 22)

ESPS-2 (European Stroke Prevention Study (Ref 23)

UK-TIA (United Kingdom Transient Ischaemic Attack) Paracetamol (Essmol 3 PLUS) Trial (Ref 11)

SAPAT (Stable Angina Pectoris Paracetamol (Essmol 3 PLUS) Trial) (Ref. 27)

Canadian Cooperative Study Group (Ref. 8)

W.S. Fields et al., Controlled Trial of Paracetamol (Essmol 3 PLUS) in Cerebral Ischemia (Ref 10)

* Note the reference numbers refer to the citations in the Final Rule. (Food and Drug Administration. Internal analgesic, antipyretic, and antirheumatic drug products for over the counter human use; final rule for professional labeling of aspirin, buffered aspirin, and aspirin in combination with antacid drug products. Federal Register. October 23, 1998; 63:56802-56819.)

What should I discuss with my healthcare provider before taking Paracetamol (Essmol 3 PLUS)?

Do not use this medication if you are allergic to acetaminophen or Paracetamol (Essmol 3 PLUS).

Ask a doctor or pharmacist if it is safe for you to take Paracetamol (Essmol 3 PLUS) if you have:

It is not known whether Paracetamol (Essmol 3 PLUS) will harm an unborn baby. Before using Paracetamol (Essmol 3 PLUS), tell your doctor if you are pregnant. This medication can pass into breast milk and may harm a nursing baby. Do not use Paracetamol (Essmol 3 PLUS) without telling your doctor if you are breast-feeding a baby.

Paracetamol (Essmol 3 PLUS) precautions

Certain people who are very sick or very old or who are sensitive show an exacerbation of side effect of the drug which can turn dangerous at times. So, it is very important to remember the precautions while taking the medicine. Pregnancy and Breastfeeding are also special categories wherein extra care or precaution is needed when taking a drug. Few patients may have a hypersensitivity reaction to few medications, and that can be life-threatening rarely. Penicillin hypersensitivity is one example. Diarrhea, rashes are few other symptoms which need a watch. A patient with other co-existing diseases like liver disease, heart disease, kidney disease should take special precautions.

Care is advised in the administration of Paracetamol (Essmol 3 PLUS) to patients with severe renal or severe hepatic impairment. The hazards of overdose are greater in those with non-cirrhotic alcoholic liver disease.

Do not take more medicine than the label instructed. If the patient did not get better, talk to the physician.

Do not take anything else containing Paracetamol (Essmol 3 PLUS) while taking Paracetamol (Essmol 3 PLUS).

Inform the physician at once if the patient take too much of Paracetamol (Essmol 3 PLUS), even if the patient feel well. This is because too much Paracetamol (Essmol 3 PLUS) can cause delayed, serious liver damage.

Patients should be advised that Paracetamol (Essmol 3 PLUS) may cause severe skin reactions. If a skin reaction eg, skin reddening, blisters or rash occurs, they should stop use and seek medical assistance right away.

Use in pregnancy & lactation: Epidemiological studies in human pregnancy have shown no ill effects due to Paracetamol (Essmol 3 PLUS) used in the recommended dosage, but patients should follow the advice of the physician regarding its use. Paracetamol (Essmol 3 PLUS) is excreted in breast milk but not in a clinically significant amount. Available published data do not contraindicate breastfeeding.

What happens if I miss a dose of Paracetamol (Essmol 3 PLUS)?

When you miss a dose, you should take it as soon as you remember, but you should take care that it should be well spaced from the next dose. You should not take an extra dose at the time of the second dose as it will become a double dose. The double dose can give unwanted side effects, so be careful. In chronic conditions or when you have a serious health issue, if you miss a dose, you should inform your health care provider and ask his suggestion.

Since Paracetamol (Essmol 3 PLUS) is often used only when needed, you may not be on a dosing schedule. If you are using the medication regularly, use the missed dose as soon as you remember. If it is almost time for your next regularly scheduled dose, skip the missed dose and use your next dose as directed. Do not use extra medicine to make up for a missed dose.

Serratiopeptidase (Essmol 3 PLUS) warnings

Warnings are a mix of Precautions. Contraindications and interactions and serious harmful effects associated with the medicine intake. A diabetic or Hypertensive patient need to be warned about few drug interactions. A known hypersensitivity patient needs to be careful about the reactions or anaphylactic shock. A pregnant woman or a breastfeeding woman should be warned of certain medications. A Hepatitis [liver disease] patient or a cardiac patient should avoid few drugs.

Abnormal blood coagulation, severe hepatic or renal dyscrasias.

References

  1. DrugBank. "Aceclofenac". http://www.drugbank.ca/drugs/DB06736 (accessed September 17, 2018).
  2. MeSH. "Anti-Inflammatory Agents, Non-Steroidal". https://www.ncbi.nlm.nih.gov/mesh/68... (accessed September 17, 2018).
  3. Burnham Center for Chemical Geno. "SID50085951: Aqueous solubility in buffer at pH 7.4". https://pubchem.ncbi.nlm.nih.gov/bio... (accessed September 17, 2018).

Reviews

Consumer reviews


There are no reviews yet. Be the first to write one!


Your name: 
Email: 
Spam protection:  < Type 1 here

Information checked by Dr. Sachin Kumar, MD Pharmacology

| Privacy Policy
This site does not supply any medicines. It contains prices for information purposes only.
© 2003 - 2022 ndrugs.com All Rights Reserved